Physicians consider the approval of Kisunla an important step after decades of failed experimental treatments, offering hope to patients and families impacted by Alzheimer's.
The delay in cognitive decline from drugs like Kisunla and Leqembi is modest, around seven months, prompting a need for careful consideration of benefits against potential risks like side effects and IV infusions.
Collection
[
|
...
]